Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles
Cellulite Cream

Macular Degeneration: The 'See Food' Diet
Current research suggests that a diet high in omega-3 fatty acids may help prevent one of the leading causes of legal blindness among the elderly. The related report by Tuo et al, "A high omega-3 fatty acid diet reduces retinal lesions in a murine model of macular degeneration," appears in the August 2009 issue of the American Journal of Pathology.
generic viagra online
AACE Response To Insulin Glargine Cancer Risk Articles In Diabetologia
On June 26, 2009 several articles published online in Diabetologia by the European Association for the Study of Diabetes investigated the possible relationship between use of insulin glargine (Lantus, sanofi-aventis) and the development of certain malignancies. The authors themselves, and the accompanying editorial, cautioned against over-interpretation of their limited data and analyses, which precluded them from drawing any firm conclusions. For example, there were contradictory findings among the studies, patient populations were not always comparable, and the duration of observation was short. Nonetheless, since the relationship of type 2 diabetes to cancer is of critical importance, further study is warranted.
News of the day
Studies Examine Morning Sickness Drug, Progesterone Use To Prevent Premature Birth
The following summarizes news coverage on two pregnancy-related studies. ~ Morning sickness: The commonly prescribed heartburn drug metoclopramide -- sold generically and under the brand-names Reglan, Octamide and Maxolon -- can be used to treat morning sickness without harming the health of the fetus, according to a study published on Thursday in the New England Journal of Medicine, Time reports. The drug, which also has anti-nausea properties, is not FDA-approved for use in pregnant women in the U.S., though it is commonly prescribed in European and other countries to treat morning sickness (Park, Time, 6/10). According to the Los Angeles Times, U.S. physicians occasionally prescribe metoclopramide to treat severe morning sickness cases. The new study found that there were no statistically significant differences between infants born to women who took metoclopramide and those who did not. Researchers said that the findings "provide reassurance regarding the safety of metoclopramide for the fetus when the drug is given to women to relieve nausea and vomiting during pregnancy." The study involved 81,703 births among women enrolled in Israel"s largest health HMO, including 33,458 who used the drug (Maugh, Los Angeles Times, 6/11). Jennifer Niebyl, a professor of obstetrics and gynecology at the University of Iowa, said, "There are very few drugs approved for use in the first trimester of pregnancy. But this study could lead to metoclopramide getting approved to treat morning sickness because this is good data with big numbers" (Time, 6/10).~ Progesterone: The hormone progesterone was not effective at preventing premature births among women pregnant with twins, despite evidence suggesting its effectiveness at preventing premature births in single pregnancies, according to a University of Edinburgh study published in the journal Lancet, Reuters reports. Multiple pregnancies have a larger health risk for women and significantly increase the likelihood of miscarriage, premature birth and long-term health problems. The study involved 500 women who took either progesterone or a placebo daily for 10 weeks. Although previous studies have shown that progesterone might prevent premature birth in certain high-risk pregnancies, the new findings show the treatment did not reduce the likelihood of premature delivery or a fetus dying in utero in twin pregnancies. Twenty-five percent of women delivered or had a fetus die before 34 weeks in the progesterone group, compared with 20% in the placebo group (Kahn, Reuters, 6/10).
Endocrinology

Quantum Immunologics, A Major Mentor Capital Investee, Starts FDA-Authorized Breast Cancer Trials

Mentor Capital, Inc. (Pink Sheets:MNTR) announces that Quantum Immunologics, Inc. (QI) has met a significant milestone marking the beginning of its FDA-authorized breast cancer trial, the completion of the first clinical treatment injection. Mentor Capital, Inc. is the largest single shareholder in QI and looks to provide equity funding throughout the trials, assist QI in funding future strategic stock or cash acquisitions, and to stand by as a preferred funding for QI during later stage or additional trials. Calculated at the current QI private placement price, Mentor Capital holds approximately $3.74 in QI stock per Mentor share, and QI represents the majority of Mentor Capital"s portfolio assets. Quantum Immunologics is based in Tampa, Florida and focuses on cancer immunotherapies. This research and development company is currently sponsoring and conducting an FDA-authorized Phase I/II clinical trial testing the safety and efficacy of its immunotherapy on twenty-seven Stage IV breast cancer patients who have failed conventional therapy. The first patient in the breast cancer trial has begun to receive QI"s dendritic cell therapy. According to Mr. Chuck Broes, CEO of QI, "This achievement marks a significant milestone in the life cycle of our company, and we look forward with great hope and commitment as we aspire to a successful trial outcome." Chet Billingsley, CEO of Mentor Capital, adds, "The successful initiation of concurrent Phase I/II trials represents an important step in the value equation for QI. Comparing the cost to acquire 20% of other dendritic immunotherapy companies, like Dendreon (DNDN), with Mentor Capital, which holds 20% of QI, will reveal attractive buying opportunities for biotechnology investors, now that QI is at the clinical stage." QI"s clinical trial is designed around the use of QI"s proprietary dendritic cell therapy, which employs oncofetal antigen (OFA) to recruit the patient"s own immune system to target and attack the cancer cells with the intent to improve patient survivability and quality of life. Each patient will receive three monthly injections of the patient"s own dendritic cells that have been sensitized to OFA. It is anticipated that once the sensitized cells are injected back into the patient, the patient"s T-cells will locate the OFA found on the patient"s cancer cells, thereby generating an immune response with the goal of killing the cancer cells and preventing further spread of the disease. Further information on Quantum Immunologics, including a summarizing video of the QI breast cancer treatment methodology that is now in FDA trials, may be found at their company web site: http://www.QuantumImmunologics.com. Comprehensive information on Mentor Capital, including capital structure detail, can be found at: http://www.MentorCapital.com. Level II quotes, news, financial information and trading charts may be referenced at http://www.PinkSheets.comunder the trading symbol MNTR. Quantum Immunologics


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009